A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy

NCT02365649 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
220
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

AbbVie